Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
The p53 tumor suppressor is a potent transcription factor that plays a key role in the regulation of cellular responses to stress. It is controlled by its negative regulator MDM2, which binds directly to p53 and inhibits its transcriptional activity. MDM2 also targets p53 for degradation by the proteasome. Many tumors produce high levels of MDM2, thereby impairing p53 function. Restoration of p53 activity by inhibiting the p53-MDM2 interaction may represent a novel approach to cancer treatment. RG7112 (2g) is the first clinical small-molecule MDM2 inhibitor designed to occupy the p53-binding pocket of MDM2. In cancer cells expressing wild-type p53, RG7112 stabilizes p53 and activates the p53 pathway, leading to cell cycle arrest, apoptosis, and inhibition or regression of human tumor xenografts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“By binding to MDM2, RG-7112 inhibits the interaction between p53 and MDM2, preventing the degradation of the p53 proteasome, which leads to stabilization and increased levels of the tumor suppressor protein p53 in the cell.369”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [369]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“MDM4 amplification was even shown to reduce sensitivity of cells to Nutlin-3 [29–31].”
From Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2 -Amplified and TP53 Wild-type Glioblastomas (2016) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“WB138 increases the levels of both p53 and MDM2, which is consistent with the activity of previous reports on MDM2 inhibitors[28,32–36].”
From Development of MDM2 degraders based on ligands derived from Ugi reactions: Lessons and discoveries (2021) · cites this paper as [35]
In the citing paper
“RG7112 was modified by Roche based on the structure of Nutlins and was the first to be introduced into clinical trials (Fig. 4) [19].”
From Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials (2022) · cites this paper as [19]
In the citing paper
“The crystal structure showed that the 4-chlorophenyl ring occupied the Trp23 and Leu26 pockets, while the ethoxy group was prominently located in the Phe19 pocket341 (Fig. 8d).”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [341]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Self-citationRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
The p53 pathway: positive and negative feedback loops
Harris, S. L., & Levine, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208615 · Cited by 1,967
p53 and Human Cancer: The First Ten Thousand Mutations
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60785-x · Cited by 986
Awakening guardian angels: drugging the p53 pathway
Brown, C. J., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2763 · Cited by 881
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy
Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708
Self-citation
Research works printed but not linked: 2
- Iwakuma T., 2003, Mol. Cancer Res., 1, 993
- Vu B. T., 2011, Curr. Top. Microbiol. Immunol., 348, 151
Cited by
Items 201–300 of 453
Conlon, I. L., Drennen, B., Lanning, M. E., Hughes, S., Rothhaas, R., Wilder, P. T., MacKerell, A. D., & Fletcher, S. (2020) · ChemMedChem · doi:10.1002/cmdc.202000278 · Cited by 17
Yokomine, M., Morimoto, J., Fukuda, Y., Ueda, T., Takeuchi, K., Umezawa, K., Ago, H., Matsuura, H., Ueno, G., Senoo, A., et al. (2024) · Chemical Science · doi:10.1039/d4sc01540a · Cited by 16
Discovery of therapeutic targets in cancer using chromatin accessibility and transcriptomic data
Forbes, A. N., Xu, D., Cohen, S. M., Pancholi, P., & Khurana, E. (2024) · Cell Systems · doi:10.1016/j.cels.2024.08.004 · Cited by 15
Sandoval, J. E., & Reich, N. O. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.010827 · Cited by 16
Ubiquitination of Nonhistone Proteins in Cancer Development and Treatment
Zhang, X., Meng, T., Cui, S., Feng, L., Liu, D., Pang, Q., & Wang, P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.621294 · Cited by 16
A role for bioinorganic chemistry in the reactivation of mutant p53 in cancer
Miller, J. J., Kwan, K., Gaiddon, C., & Storr, T. (2022) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-022-01939-2 · Cited by 16
Targeting biologically specific molecules in triple negative breast cancer (TNBC)
Mir, M. A., Sofi, S., & Qayoom, H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-96136-3.00002-9 · Cited by 16
Romani, A., Zauli, E., Zauli, G., Al-Mesfer, S., Al-Swailem, S. A., & Voltan, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1000677 · Cited by 16
Molecularly Targeted Therapies in Oncology: Mechanisms, Resistance, and Combination Strategies
Giercuszkiewicz-Haśnik, K., MORAK-MŁODAWSKA, B. I., & Jeleń, M. (2026) · Molecules · doi:10.3390/molecules31071195 · Cited by 15
Yang, W., Wang, J., Zhao, L., & Chen, J. (2024) · Molecules · doi:10.3390/molecules29143377 · Cited by 15
Perspectives on drug discovery strategies based on IDPs
Fuertes, G., Nevola, L., & Esteban-Martín, S. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816348-1.00009-0 · Cited by 15
The MDM2 Inhibitor Navtemadlin Arrests Mouse Melanoma Growth In Vivo and Potentiates Radiotherapy
Ingelshed, K., Spiegelberg, D., Kannan, P., Påvénius, L., Hacheney, J., Jiang, L., Eisinger, S., Lianoudaki, D., Lama, D., Castillo, F. A., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0053 · Cited by 15
Pan, W., Lahue, B. R., Ma, Y., Nair, L. G., Shipps, G. W., Wang, Y., Doll, R. J., & Bogen, S. L. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.02.055 · Cited by 15
Targeting Cullin-RING Ubiquitin Ligases and the Applications in PROTACs
Gong, L., Cui, D., Xiong, X., & Zhao, Y. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-1025-0_19 · Cited by 15
Zhou, W.-H., Xu, X., Li, J., Min, X., Yao, J., Dong, G., Zhuang, C., Miao, Z., & Zhang, W. (2016) · Chinese Chemical Letters · doi:10.1016/j.cclet.2016.09.001 · Cited by 15
Discovering Putative Protein Targets of Small Molecules: A Study of the p53 Activator Nutlin
Nguyen, M. N., Sen, N., Lin, M., Joseph, T. L., Vaz, C., Tanavde, V., Way, L., Hupp, T. R., Verma, C. S., & Madhusudhan, M. S. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00762 · Cited by 15
Xie, F., Niu, Y., Chen, X., Kong, X., Yan, G., Zhuang, A., Li, X., Lian, L., Qin, D., Zhang, Q., et al. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.101068 · Cited by 14
Advances in drug development for targeted therapies for glioblastoma
Ge, Y., Wang, Y., Chen, J., Zheng, W., Liu, C., Chen, S., Wang, L., Luo, J., & Li, Z. (2020) · Medicinal Research Reviews · doi:10.1002/med.21676 · Cited by 14
Zaytsev, A. V., Dodd, B., Magnani, M., Ghiron, C., Golding, B. T., Griffin, R. J., Liu, J., Lü, X., Micco, I., Newell, D. R., et al. (2014) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12474 · Cited by 14
Self-citationDevelopment of MDM2‐Targeting PROTAC for Advancing Bone Regeneration
Jeong, S., Cha, J., Ahmed, W., Kim, J., Kim, M., Hong, K. T., Choi, W., Choi, S., Yoo, T. H., An, H., et al. (2025) · Advanced Science · doi:10.1002/advs.202415626 · Cited by 13
Giardina, S. F., Valdambrini, E., Singh, P. K., Bacolod, M. D., Babu-Karunakaran, G., Peel, M. R., Warren, J. D., & Barany, F. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02097 · Cited by 13
Molecular Targeting of the Most Functionally Complex Gene in Precision Oncology: p53
Brown, D. W., Beatty, P. H., & Lewis, J. D. (2022) · Cancers · doi:10.3390/cancers14215176 · Cited by 13
MDM2 Antagonists Counteract Drug-Induced DNA Damage
Vilgelm, A. E., Cobb, P., Malikayil, K. L., Flaherty, D. K., Johnson, C. A., Raman, D., Saleh, N., Higgins, B., Vara, B., Johnston, J. N., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.09.016 · Cited by 13
Targeting p53 activation: Recent therapeutic advances in cancer and diabetic macular edema
Wang, Z., Zhang, S., Mélita, I. L., & Zhao, Y. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117909 · Cited by 12
Ma, J., Ni, X., Gao, Y., Huang, K., Wang, Y., Liu, J., & Gong, G. (2019) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c18-00738 · Cited by 12
Self-citationWang, X., Li, Y.-R., Wu, J., Niu, J.-B., Song, J. H., & Zhang, S. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117328 · Cited by 11
Epigenetic Alterations in Cancer: The Therapeutic Potential of Epigenetic Drugs in Cancer Therapy
Gupta, P. (2025) · Drugs and Drug Candidates · doi:10.3390/ddc4020015 · Cited by 11
Ray, S., & Hewitt, K. J. (2023) · BioEssays · doi:10.1002/bies.202300022 · Cited by 11
Yu, B., & Liu, H. (2018) · Springer eBooks · doi:10.1007/978-981-13-0773-7_8 · Cited by 11
E3 Ubiquitin Ligases in Cancer and Their Pharmacological Targeting
Ong, J. Y., & Torres, J. Z. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82883 · Cited by 11
State of the Art of Pharmacological Activators of p53 in Ocular Malignancies
Casciano, F., Zauli, E., Busin, M., Caruso, L., Al-Mesfer, S., Al-Swailem, S. A., Zauli, G., & Yu, A. C. (2023) · Cancers · doi:10.3390/cancers15143593 · Cited by 11
Identification of a Structural Determinant for Selective Targeting of HDMX
Ben‐Nun, Y., Seo, H., Harvey, E. P., Hauseman, Z. J., Wales, T. E., Newman, C. E., Cathcart, A. M., Engen, J. R., Dhe‐Paganon, S., & Walensky, L. D. (2020) · Structure · doi:10.1016/j.str.2020.04.011 · Cited by 10
Kang, J. H., Lee, S.-H., Lee, J., Oh, S. J., Ha, J. S., Choi, H.-J., & Kim, S. (2020) · Cells · doi:10.3390/cells9061475 · Cited by 10
Design and In Silico Study of the Novel Small Molecular MDM2 Inhibitors
(2020) · Biointerface Research in Applied Chemistry · doi:10.33263/briac111.80528064 · Cited by 10
p52-ZER6: a determinant of tumor cell sensitivity to MDM2-p53 binding inhibitors
Li, W., Alfason, L., Huang, C., Tang, Y. R., Li, Q., Miyagishi, M., Wu, S., & Kasim, V. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00973-9 · Cited by 10
Targeting protein-protein interaction interfaces with antiviral N protein inhibitor in SARS-CoV-2
Hong, J.-Y., Lin, S., Kehn‐Hall, K., Zhang, K., Luo, S., Wu, H., Chang, S., & Hou, M. (2024) · Biophysical Journal · doi:10.1016/j.bpj.2024.01.013 · Cited by 10
Chen, R., Zhou, J., Qin, L., Chen, Y., Huang, Y., Liu, H., & Su, Z. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00085 · Cited by 10
Na, I., Choi, S., Son, S. H., Uversky, V. N., & Kim, C. G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155248 · Cited by 10
The Potential Role of Histone Modifications in Glioblastoma Therapy: Review Article
Azab, M. A. (2023) · Journal of Molecular Pathology · doi:10.3390/jmp4040018 · Cited by 9
Hu, Q.-Y., Li, L., Li, Y.-H., Zhang, H., Deng, T., Liu, Y., Li, F.-T., Xiao, Z. J., & Cao, Y. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01394-6 · Cited by 9
Ria, F., Pirolli, D., Sante, G. D., Righino, B., Gremese, E., Gervasoni, J., Nicolò, C., Giardina, B., Ferraccioli, G., & Rosa, M. C. D. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00601 · Cited by 9
Wang, C., & Sallman, D. A. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000569 · Cited by 9
Synthetic approaches to constructing proteolysis targeting chimeras (PROTACs)
Bakulina, O., Sapegin, A., Bunev, A. S., & Krasavin, M. (2022) · Mendeleev Communications · doi:10.1016/j.mencom.2022.07.001 · Cited by 9
Mitobe, Y., Suzuki, S., Nakagawa-Saito, Y., Togashi, K., Sugai, A., Sonoda, Y., Kitanaka, C., & Okada, M. (2023) · Cancers · doi:10.3390/cancers15174326 · Cited by 9
MDM2/P53 Inhibitors as Sensitizing Agents for Cancer Chemotherapy
Zhu, Y. Y., Wang, H., & Thuraisamy, A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816435-8.00015-8 · Cited by 9
Wu, L., Yang, Y., Wang, Z., Wu, X., Su, F., Li, M., Jing, X., & Han, C. (2020) · Molecules · doi:10.3390/molecules25051162 · Cited by 9
Sun, X., Lu, Z.-Y., Liang, Z., Deng, B., Zhu, Y., Shi, J., & Lü, X. (2022) · Molecules · doi:10.3390/molecules27206958 · Cited by 9
Sheng, C., Dong, G., Miao, Z., Zhang, W., & Wang, W. (2015) · Chemical Society Reviews · doi:10.1039/c5cs90090e · Cited by 9
Siriki, A., Ragland, G., Vasireddy, J., & Chitneni, S. K. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130394 · Cited by 8
Lin, Z., Liu, C., Yan, Z., Cheng, J., Wang, X., Zhou, F., Lyu, X., Zhang, S., Zhang, D., Meng, X., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116366 · Cited by 8
A Primer on the Role of TP53 Mutation and Targeted Therapy in Endometrial Cancer
Zhang, B., Zhang, H., & Qin, Y. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl25447 · Cited by 8
Albadari, N. G., Xie, Y., Liu, T., Wang, R., Gu, L., Zhou, M., Wu, Z., & Li, W. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115423 · Cited by 8
Signal Pathways and Therapeutic Prospects of Diffuse Large B Cell Lymphoma
Sun, F., Fang, X., & Wang, X. (2019) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520619666190925143216 · Cited by 8
Zhao, X., Xiong, D., Luo, S., & Duan, L. (2022) · Physical Chemistry Chemical Physics · doi:10.1039/d2cp01780f · Cited by 8
Wang, X., Chen, Y., Liu, H., Guo, S., Hu, Y., Zhan, Y., & An, H. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.07.106 · Cited by 8
Polycythemia vera: the current status of preclinical models and therapeutic targets
Bartalucci, N., Guglielmelli, P., & Vannucchi, A. M. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1762176 · Cited by 8
Al‐Ali, H. K., Heidel, S. T., Palandri, F., & Heidel, F. H. (2026) · Leukemia · doi:10.1038/s41375-026-02975-6 · Cited by 7
The MDM2–p53 Axis Represents a Therapeutic Vulnerability Unique to Glioma Stem Cells
Nakagawa-Saito, Y., Mitobe, Y., Togashi, K., Suzuki, S., Sugai, A., Takenouchi, S., Nakamura, K., Sonoda, Y., Kitanaka, C., & Okada, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073948 · Cited by 7
Pharmacological Inhibition of MDM2 Induces Apoptosis in p53-Mutated Triple-Negative Breast Cancer
On, J. L., Ghaderi, S., Rittmann, C., Hoffmann, G., Gier, F., Woloschin, V., Tu, J., Bhatia, S., Kulik, A., Niederacher, D., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031078 · Cited by 7
Dual functionality of MDM2 in PROTACs expands the horizons of targeted protein degradation
Zhao, J., Chen, H., & Liang, C. (2025) · Biomarker Research · doi:10.1186/s40364-025-00826-7 · Cited by 7
Wang, W., Alley, A., Sun, N., Tadesse, M., Wang, X., & Zhang, R. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1663766 · Cited by 7
SNPs Give LACTB Oncogene‐Like Functions and Prompt Tumor Progression via Dual‐Regulating p53
Huang, G., Zhang, J., Xu, Y., Wu, F. L., Fu, Y., Zhang, X., Yin, H., You, Y., Zhao, P., Liu, W., et al. (2024) · Advanced Science · doi:10.1002/advs.202405907 · Cited by 7
Frosi, Y., Inoue, K., Ramlan, S. R., Lane, D. P., Watanabe, T., & Brown, C. J. (2019) · Scientific Reports · doi:10.1038/s41598-019-54123-z · Cited by 7
Nietzold, F., Rubner, S., Łabuzek, B., Golik, P., Surmiak, E., del Corte, X., Kitel, R., Protzel, C., Reppich, R., Stichel, J., et al. (2023) · ChemBioChem · doi:10.1002/cbic.202300006 · Cited by 7
Sana, B., Chee, S. M. Q., Wongsantichon, J., Raghavan, S. S., Robinson, R. C., & Ghadessy, F. J. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.007141 · Cited by 7
Can the New and Old Drugs Exert an Immunomodulatory Effect in Acute Myeloid Leukemia?
Tarantini, F., Cumbo, C., Anelli, L., Zagaria, A., Specchia, G., Musto, P., & Albano, F. (2021) · Cancers · doi:10.3390/cancers13164121 · Cited by 7
Exosomal dynamics: Bridging the gap between cellular senescence and cancer therapy
Aswani, B. S., Sajeev, A., Hegde, M., Mishra, A., Abbas, M., Vayalpurayil, T., Sethi, G., & Kunnumakkara, A. B. (2025) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2025.112045 · Cited by 6
Guan, Y., Bai, X., Li, C., Zhang, Z., He, Q., Chen, L., Xie, Y., & Wang, Z. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101871 · Cited by 6
The Structure, Pathogenesis, and Inhibition of the p53-MDM2 Pathway
Brown, A. L., Lian, X., & Wang, Q. (2026) · Cancers · doi:10.3390/cancers18040546 · Cited by 6
Targeting mutant p53 in cancer: from mechanistic insights to therapeutic strategies
Wu, H. H., Leng, S., Eisenstat, D. D., Sergi, C. M., & Leng, R. P. (2026) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-026-00907-x · Cited by 6
Targeting Protein–Protein Interactions Perspective
Chung, C., & Hann, M. M. (2020) · Wiley eBooks · doi:10.1002/9781118681121.ch20 · Cited by 6
Alali, H., Bloch, I., Rapaport, I., Rodrigues, L., Sher, I., Ansbacher, T., & Gal, M. (2022) · Pharmaceuticals · doi:10.3390/ph15060752 · Cited by 6
Targeting MDM2 for the development of a new cancer therapy: progress and challenges
Aguilar, A., Thomas, J. E., & Wang, S. (2023) · Medicinal Chemistry Research · doi:10.1007/s00044-023-03102-1 · Cited by 6
Expeditious Synthesis and Biological Characterization of Enantio‐Enriched (‐)‐Nutlin‐3
Fantinati, A., Bianco, S., Cristofori, V., Cavazzini, A., Catani, M., Zanirato, V., Pacifico, S., Rimondi, E., Milani, D., Voltan, R., et al. (2017) · ChemistrySelect · doi:10.1002/slct.201701059 · Cited by 6
Mukherjee, A., Yadav, P. H., & Mukunthan, K. S. (2023) · Molecular Biotechnology · doi:10.1007/s12033-023-00879-9 · Cited by 6
Kwan, K., Castro-Sandoval, O., Ma, B. N., Martelino, D., Saffari, A., Liu, X. L., Orvain, C., Mellitzer, G., Gaiddon, C., & Storr, T. (2023) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2023.112433 · Cited by 6
The Evolution of Tumor Formation in Humans and Mice with Inherited Mutations in the p53 Gene
Levine, A. J. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_5 · Cited by 6
Bradbury, R., Jiang, W. G., & Cui, Y. (2015) · Biomarkers in Medicine · doi:10.2217/bmm.15.94 · Cited by 6
Sun, H., Coussens, N. P., Danchik, C., Wachsmuth, L. M., Henderson, M. J., Patnaik, S., Hall, M. D., Molinaro, A. L., Daines, D. A., & Shen, M. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01188 · Cited by 6
Targeting Protein Synthesis, Folding, and Degradation Pathways in Cancer
Pasqua, E., Wilding, B., Cheeseman, M. D., & Jones, K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12395-9 · Cited by 6
Asymmetrically Substituted m‐Terphenyl Phosphates Inhibit the Transcription Factor STAT5a
Müller‐Klieser, D., & Berg, T. (2021) · ChemBioChem · doi:10.1002/cbic.202100603 · Cited by 5
Xie, J., Shu, X., Xie, Z., Tang, J., & Guo, W. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177475 · Cited by 5
Protein–Protein Interaction Inhibitors in Cancer
Hardcastle, I. R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12392-3 · Cited by 5
Proteasome Based Molecular Strategies Against Improper Cellular Proliferation
Dubey, A. R., Kinger, S., Jagtap, Y. A., Patwa, S. M., Kumar, P., Singh, S., Kumar, A., Kumar, A., & Mishra, A. (2021) · Cellular Physiology and Biochemistry · doi:10.33594/000000439 · Cited by 5
Non-enzymatic protein targeting agents as a promising strategy for cancer treatment
Ambrose, M., Lee, J., Syed, A., Ahmed, Z., & Peng, G. (2025) · Frontiers in Drug Discovery · doi:10.3389/fddsv.2025.1520734 · Cited by 4
Yang, J., Huang, W., Yao, Z., He, Z., Meng, S., & Xu, L. (2025) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5c01516 · Cited by 4
Wang, C., Chen, B., Yang, H., Huang, C., Zhang, Y., Yan, J., Zhang, D., Huang, A., Wu, Y., Zhu, J., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01003 · Cited by 4
The evolution of Nutlins as p53-MDM2 inhibitors
Bazanov, D. R., & Lozinskaya, N. A. (2025) · Medicinal Chemistry Research · doi:10.1007/s00044-025-03492-4 · Cited by 4
Singh, M., Upreti, A., Chattopadhyay, S., & Santra, M. K. (2025) · Essays in Biochemistry · doi:10.1042/ebc20253037 · Cited by 4
Ma, J., Yuan, J., & Lv, H. (2026) · Nature Communications · doi:10.1038/s41467-025-67526-6 · Cited by 4
Cristofori, V., Illuminati, D., Bisquoli, C., Catani, M., Compagnin, G., Turrin, G., Trapella, C., & Fantinati, A. (2024) · Molecules · doi:10.3390/molecules29143267 · Cited by 4
Yang, J., He, Z., Yao, Z., Huang, W., Meng, S., Xu, L., & Fan, Q. (2025) · Organic Chemistry Frontiers · doi:10.1039/d5qo00625b · Cited by 4
MDM2 as a therapeutic target in advanced biliary tract cancers
Spencer, K. R., & King, G. T. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf094 · Cited by 4
Kantarci-Carsibasi, N. (2021) · Journal of Computational Biophysics and Chemistry · doi:10.1142/s2737416521500460 · Cited by 4
Lukyanenko, E. R., Belov, G. M., Novoselov, A. M., Nechaev, M. S., & Kurkin, A. V. (2022) · New Journal of Chemistry · doi:10.1039/d2nj03936b · Cited by 4
Mehri, A., Mardanshahi, M., Sirous, H., Khanahmad, H., & Rostami, M. R. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0012 · Cited by 4
Drug Design Methods to Regulate Protein–Protein Interactions
Poluri, K. M., Gulati, K., Tripathi, D. K., & Nagar, N. (2023) · Springer eBooks · doi:10.1007/978-981-99-2423-3_6 · Cited by 4
Case Study: Discovery of Inhibitors of the MDM2–p53 Protein-Protein Interaction
Liu, L., Bernard, D., & Wang, S. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2425-7_38 · Cited by 4
Development and structural characterisation of human scFv targeting MDM2 spliced variant MDM215kDa
Lim, C. C., Chan, S. K., Lim, Y. Y., Ishikawa, Y., Choong, Y. S., Nagaoka, Y., & Lim, T. S. (2021) · Molecular Immunology · doi:10.1016/j.molimm.2021.04.016 · Cited by 4
Basha, N. J., & Mohan, R. M. (2024) · ChemistrySelect · doi:10.1002/slct.202304525 · Cited by 4
Metadata
- Authors
- Vu, B., Wovkulich, P., Pizzolato, G., Lovey, A., Ding, Q., Jiang, N., Liu, J.-J., Zhao, C., Glenn, K., Wen, Y., Tovar, C., Packman, K., Vassilev, L., & Graves, B.
- Affiliations
- F. Hoffmann-La Roche AG (CH)
- Discovery Chemistry, ‡Discovery Oncology, §Discovery Technologies, ∥Non-Clinical Development, Roche Research Center, Hoffmann-La Roche, Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
- Corresponding author
- Vu, Binh
- ORCID
- Venue
- ACS Medicinal Chemistry Letters
- Publisher
- American Chemical Society (ACS)
- Published
- 2013-04-04
- Volume
- 4
- Issue
- 5
- Pages
- 466-469
- ISSN
- 1948-5875 (ISSN-L)
- PMC
- PMC4027145
- OpenAlex
- W1985567682
- Cited by
- 395
- References
- 24
- Citations by year
- 2026: 22 · 2025: 42 · 2024: 28 · 2023: 39 · 2022: 39 · 2021: 36 · 2020: 39 · 2019: 39 · 2018: 19 · 2017: 19 · 2016: 16 · 2015: 28 · 2014: 20 · 2013: 8
- FWCI
- 13.93
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- ACS Medicinal Chemistry Letters (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- RG7112, MDM2 inhibitors, p53, p53-MDM2 interaction, small molecule drug discovery, p53 stabilization, cancer therapy, cell cycle arrest, apoptosis, tumor xenografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.